Trial Profile

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Cisplatin
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
Focus Therapeutic Use

Most Recent Events

26 Nov 2024 Planned End Date changed from 31 Oct 2024 to 15 Mar 2025.
22 Oct 2024 Planned End Date changed from 1 Jul 2024 to 31 Oct 2024.
17 May 2024 Planned End Date changed from 1 May 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com